FDA must immediately suspend abortion drug approval

The FDA's recent approval of a second generic abortion pill, mifepristone, by Evita Solutions, has sparked significant controversy, especially among pro-life advocates. This decision echoes a previous approval during President Trump's term, raising concerns about the implications for women's health and the ongoing debate surrounding abortion rights. The approval is seen by many as a step backward in the fight against abortion, highlighting the tensions between regulatory decisions and societal values.